Skip to main content

Table 2 Adverse reactions resulting in discontinuation of cART, n (%)

From: Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults

Patients with ≥ 1 adverse reaction23
Total number of adverse reactions28
Types of adverse reaction 
 Dermatological12 (42.9)
 Gastrointestinal/hepatic2 (7.1)
 Neuropsychiatric13 (46.4)
 Endocrine/metabolic1 (3.6)
Severity of adverse reaction 
 Mild (symptoms do not require major medical intervention)25 (89.3)
 Moderate (requires medical treatment or hospitalisation)3 (10.7)
 Severe (fatal or life threatening)0 (0)